421 results on '"Heslop, H"'
Search Results
2. T Cell Therapies
3. T-Cell Therapies for EBV-Associated Malignancies
4. Adoptive Immunotherapy of EBV-Associated Malignancies with EBV-Specific Cytotoxic T-Cell Lines
5. Hematopoietic Stem/Progenitor Cells and Engineering: Late Breaking Abstract: ALLOGENEIC DONOR-DERIVED CD19-CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR RELAPSED B-CELL MALIGNANCIES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
6. Immunotherapy: EPSTEIN-BARR VIRUS (EBV) SPECIFIC T-CELLS WITH BROADER TARGET ANTIGEN REPERTOIRE FOR THE TREATMENT OF EBV+ MALIGNANCIES
7. Engineering haploidentical transplants
8. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals
9. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
10. Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine
11. Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD
12. ULTRA LOW-DOSE IL-2 MEDIATED EXPANSION OF REGULATORY T CELLS AS GVHD PROPHYLAXIS FOR RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELLS: PH-P298
13. MULTI-VIRUS-SPECIFIC T-CELL THERAPY FOR PATIENTS AFTER HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION.: PH-O028
14. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma
15. Long term follow up of subsequent malignancies in patients treated with genetically modified immune effectors
16. Adoptive cellular immunotherapy for viral diseases
17. Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation
18. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation
19. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation
20. OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL).
21. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML)
22. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath)
23. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab
24. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors
25. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen
26. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy
27. LMP-specific cytotoxic T- lymphocytes administered to EBV+ lymphoma patients after stem cell transplant: 0269
28. Cord blood-derived virus-specific cytotoxic T-lymphocyte therapy for cytomegalovirus, adenovirus, and Epstein-Barr virus: 0118
29. Basic Science Award Multi-virus-specific T-cell therapy for patients after haematopoietic stem cell transplantation: 0113
30. T Cell Therapies
31. Multi-tumor-antigen-specific cytotoxic T lymphocytes for therapy of hematologic malignancies: V739
32. Multivirus-specific T cell immunotherapy to prevent or treat infections of allogeneic stem cell transplant recipients: V329
33. Pediatric Blood and Marrow Transplantation: State of the Science
34. 21. New Immunological Principles: 112 THE USE OF AUTOLOGOUS LMP2-SPECIFIC CYTOTOXIC T LYMPHOCYTES FOR THE TREATMENT OF RELAPSED EBV + VE HODGKIN DISEASE AND NON-HODGKIN LYMPHOMA
35. T-Cell Immunotherapy for Adenoviral Infections of Stem-Cell Transplant Recipients
36. Options for T-cell based therapies
37. Dendritic cells transduced with a recombinant adenovirus efficiently direct the generation of LMP2A-specific CTL - a potent strategy in EBV+ Hodgkinʼs lymphoma immunotherapy: 398
38. 516 - Immunotherapy: EPSTEIN-BARR VIRUS (EBV) SPECIFIC T-CELLS WITH BROADER TARGET ANTIGEN REPERTOIRE FOR THE TREATMENT OF EBV+ MALIGNANCIES
39. 18 - Hematopoietic Stem/Progenitor Cells and Engineering: Late Breaking Abstract: ALLOGENEIC DONOR-DERIVED CD19-CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR RELAPSED B-CELL MALIGNANCIES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
40. Use of highly characterized EBV-Specific T Cells outside of the immediate Post-Transplant setting
41. Apport des biothérapies anticancéreuses dans le traitement des leucémies de l’enfant
42. Hepatic Arterial Resistance Index - An Indicator of Diffuse Liver Disease in Children Treated With Bone Marrow Transplantation
43. Induction of Hepatic Drug Metabolism During High Dose Preparative Chemotherapy for Bone Marrow Transplantation(BMT): PIII-36
44. Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with b cell non-hodgkin lymphoma (B-NHL): Reversal of toxicity from tonic signaling
45. Administration of T cells targeting tumor associated antigens to patients with myeloma
46. Use of highly characterized EBV-specific T cells for treatment of EBV+ lymphoma outside of the HSCT setting
47. Transgenic expression of IL15 selectively expands antigen specific cytotoxic T cells (CTLs) enhancing their anti-tumor effect in vivo
48. Chimeric Antigen Receptor Gene-Modified Virus-Specific T-Cell Expanded in Patients with Reactivated Epstein-Barr Virus Post Allogeneic Stem Cell Transplant
49. A Phase 1 Perspective: Multivirus-Specific T Cells From Both Cord Blood and Bone Marrow Transplant Donors
50. Rapidly-Generated EBV-Specific T Cells (Ebvst-Cells) to Treat Type 2 Latency Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.